ResMed (NYSE: RMD) taps Aaron Bloomer as CFO while reaffirming 2026 margin outlook
Rhea-AI Filing Summary
ResMed Inc. announced a planned chief financial officer transition. Long‑tenured CFO Brett Sandercock will retire from the CFO role effective May 4, 2026 and move into special advisory positions to support Chairman and CEO Mick Farrell during the leadership handover.
The company appointed Aaron Bloomer, formerly CFO of Exact Sciences, as the new Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, effective May 4, 2026. His package includes a $725,000 base salary, a $150,000 sign‑on bonus, and a $3.3 million sign‑on equity grant split between restricted stock units and performance stock units.
ResMed also reported third‑quarter fiscal 2026 results and reiterated its fiscal 2026 outlook, including a gross margin range of 62–63%, SG&A expenses of 19–20%, R&D expenses of 6–7%, and an effective tax rate of 21–23%.
Positive
- None.
Negative
- None.
Insights
ResMed pairs an orderly CFO succession with unchanged 2026 margin guidance.
ResMed is transitioning from long‑serving CFO Brett Sandercock to incoming CFO Aaron Bloomer on May 4, 2026. Sandercock remains in special advisory roles, which helps preserve institutional knowledge and supports continuity during the finance leadership change.
Bloomer brings experience from Exact Sciences, Baxter and 3M, with a background in global finance and operational discipline. His compensation mix of base salary, cash bonus and performance stock units tied to total shareholder return aligns incentives with shareholder outcomes and long‑term value creation goals.
Alongside the leadership update, ResMed reiterated its fiscal 2026 outlook, targeting gross margin of 62–63%, SG&A of 19–20%, R&D of 6–7% and an effective tax rate of 21–23%. Maintaining this guidance suggests the company sees no immediate financial disruption from the CFO transition based on current information.
8-K Event Classification
Key Figures
Key Terms
performance stock units financial
equity incentive plans financial
change in control arrangements financial
short-term cash incentive bonus financial
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Under Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact Name of Registrant as Specified in Charter)
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
| (Address of Principal Executive Offices) |
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading |
Name of each exchange | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On April 30, 2026, ResMed Inc. (the “Company”) announced that Brett Sandercock, Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, will retire from his role as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer.
Mr. Sandercock will continue to serve as Chief Financial Officer until May 4, 2026, immediately following which he will become Special Advisor to Mick Farrell, Chairman and Chief Executive Officer through December 31, 2026. Mr. Sandercock will continue to receive his current salary, benefits and vesting of long-term equity incentives and will remain eligible for a six month, pro-rata payment of his short-term incentive for fiscal year 2027.
From January 1, 2027, through December 31, 2027, Mr. Sandercock will continue as Special Advisor to Mr. Farrell in a consulting role. During the consulting period he will remain eligible for continued vesting of outstanding equity awards in accordance with the ordinary terms of such equity grants and our equity incentive plans.
Mr. Sandercock’s decision to retire did not result from any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.
On April 30, 2026, the Company also announced it appointed Aaron Bloomer, age 40, as Chief Financial Officer, effective May 4, 2026. Mr. Bloomer will serve as our Principal Financial Officer and Principal Accounting Officer.
Mr. Bloomer most recently served as Executive Vice President and Chief Financial Officer of Exact Sciences Corporation (NASDAQ: EXAS), where he led global finance and served as a key advisor to the CEO and Board. Prior to Exact Sciences, Mr. Bloomer held senior finance leadership roles at Baxter International Inc. (NYSE: BAX), a global medical device company, and 3M Company (NYSE: MMM), a global industrial, consumer and safety products company.
Mr. Bloomer’s compensation will include annual base salary of $725,000, a sign-on bonus of $150,000, an annual short-term cash incentive bonus target of 80% of his base salary, which will be, payable pro-rata for fiscal year 2026. The sign-on bonus is subject to repayment if Mr. Bloomer voluntarily terminates employment within 24 months of his start date. Mr. Bloomer will receive a long-term performance equity grant of $3,300,000 when he joins the Company. Consistent with the other executive team members, Mr. Bloomer’s sign-on equity grant will be divided equally between executive restricted stock units, and performance stock units. The performance stock units will be equally divided between (i) absolute total shareholder return and (ii) relative total shareholder return measured against the S&P 500. Like the rest of the executive team, the sign-on equity grant is designed to align Mr. Bloomer’s interests with long-term shareholder value creation. Mr. Bloomer will also receive relocation assistance to move to San Diego.
In addition to the foregoing, for fiscal year 2027, Mr. Bloomer will be eligible for an equity grant of $3,300,000 in November 2026, subject to review and approval by the Compensation and Leadership Development Committee of the Board of Directors.
Mr. Bloomer will also be eligible to participate in the Company’s executive severance and change in control arrangements, consistent with other senior executives of the Company.
The Company intends to file Mr. Bloomer’s signed offer letter as an exhibit to its Form 10-Q for the quarter ended March 31, 2026 and the foregoing description is qualified in its entirety by reference to such offer letter..
There are no offer or understandings between Mr. Bloomer and any other person pursuant to which he was appointed. There are no family relationships between Mr. Bloomer and any director or executive officer, and no related party transactions requiring disclosure under Item 404(a) of Regulation S-K.
-2-
On April 30, 2026, we issued a press release announcing Mr. Sandercock’s retirement and Mr. Bloomer’s appointment. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits
| Exhibits: |
Description of Document | |
| 99.1 | Press Release dated April 30, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL, document) | |
-3-
SIGNATURES
We have authorized the person whose signature appears below to sign this report on our behalf, in accordance with the Securities Exchange Act of 1934.
| Date: April 30, 2026 | ResMed Inc. | |||||
| (registrant) | ||||||
| By: | /s/ Michael J. Rider | |||||
| Name: | Michael J. Rider | |||||
| Its: | Global General Counsel and Secretary | |||||
-4-
Exhibit 99.1
| For Investors |
For Media | |||
| Salli Schwartz |
Brad Lotterman | |||
| Salli.Schwartz@resmed.com |
Brad.lotterman@resmed.com | |||
| investorrelations@resmed.com |
news@resmed.com |
Resmed Chief Financial Officer Brett Sandercock to Retire;
Aaron Bloomer Appointed as Successor
SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) — Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced that Brett Sandercock, Chief Financial Officer, plans to retire effective May 4, 2026. After conducting a comprehensive search, Aaron Bloomer has been appointed as his successor.
“After 27 years with Resmed, including 20 as CFO, Brett leaves an outstanding legacy of disciplined leadership and trusted partnership,” said Mick Farrell, Chairman and CEO of Resmed. “Brett’s leadership has helped guide Resmed through significant growth and transformation while keeping a clear focus on long-term value creation and our goal to improve more than 500 million lives. On behalf of the Board and the entire Resmed team, I thank Brett for his exceptional contributions and wish him all the best in his well-earned retirement.”
Aaron Bloomer joins Resmed from Exact Sciences, a global leader in cancer diagnostics recently acquired by Abbott, where he served as Chief Financial Officer.
Aaron brings more than 17 years of global finance and operating leadership experience, with a strong track record of driving growth, operational discipline and shareholder value creation. At Exact Sciences, he helped shape and execute a new strategic plan that delivered strong revenue growth, significant margin expansion and substantial increases in free cash flow. Aaron also strengthened capital allocation frameworks and supported strategic M&A, as well as new product launches to expand the company’s portfolio.
Previously, Aaron held senior finance leadership roles at Baxter International and 3M. Across these roles, he drove operational rigor, improved financial performance, drove transformations and led strategic initiatives including portfolio management, acquisitions and divestitures. During his more than a decade-long tenure at 3M, he served in a variety of roles including Senior Vice President of Financial Planning and Analysis, as a regional CFO based in China and a global divisional CFO based in Japan.
“Aaron is a proven financial leader with deep experience driving operational discipline, strategic growth and global financial performance. He stood out as a star during the selection process with his intelligence and experience in growth businesses,” Mick Farrell said. “We look forward to the leadership and broad perspective Aaron will bring as we continue to execute on our 2030 strategy, scale our business and drive sustainable long-term growth.”
“I’m honored to join Resmed at such an exciting time in its journey,” said Aaron Bloomer. “Resmed’s leadership in digital health and its vision to create a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home, resonates with me. I look forward to working with the team to build on its strong foundation and support continued growth and value creation.”
Brett Sandercock will serve as an advisor to the CEO through the end of calendar year 2027.
Resmed reported results for its third quarter fiscal year 2026 today and is reiterating its outlook for fiscal year 2026, including gross margin in the range of 62-63%, SG&A expenses in the range of 19-20%, R&D expenses in the range of 6-7% and effective tax rate in the range of 21-23%.
About Resmed
Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at Resmed.com and follow @Resmed.